In addition, this microRNA promotes Th17 cell differentiation through targeting SOCS3. These results facilitate better understanding of the pathogenesis of EAE and imply that miR-384 may be an effective biomarker or potential therapeutic target in MS. The gene discussed is SOCS3; the disease is myeloid sarcoma.